Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-2010 in Primary IgA Nephropathy
NCT05847920Phase 2Terminated
- Sponsor
- Hengrui Therapeutics
- Start
- Jun 2023
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in IgA nephropathy (IgAN) comparing SHR-2010 with Placebo (2 arms). Primary endpoint: Urine Protein to Creatinine Ratio at 24 weeks. Started Jun 2023; status: terminated.
02
Drugs
SHR-2010
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT05847920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05847920.